Name : potassium salts , potassium acetate , potassium chloride ,potassium gluco nate Brand Name: Oral: Apo-K (CAN),

Cena-K, Effer-K, Gen-K, Kaon-Cl, Kay Ciel, K aylixir, K-Dur 10, K-Dur 20, K-Lor, K-Tab, Klor-Con, Klorvess, Klotrix, K-Lyte/C l, Kolyum, K+ Care ET, K + 8, K + 10, Micro-K Extencaps, Potasalan, Rum-K, Ten K Injection: Potassium Chloride , Kaon, K-G Elixir, Kolyum, Tri-K, Twin-K Classification: Electrolyte Pregnancy Category C Read more at Nurseslabs.com Kalium Durule (Potassium Chloride) Drug Study http:/ /nurseslabs.com/kalium-durule-potassium-chloride-drug-study/ Dosage & Route Adult Dose for Hypokalemia Parenteral: 40 to 100 mEq potassium ch loride for injection diluted in an appropriate amount and type of solution to be intravenously infused once at a rate not to exceed 10 to 40 mEq/hour. Oral: 40 to 100 mEq orally once a day given in equally divided doses using formulations w hich include normal-release tablets or capsules, extended-release tablets or cap sules, dissolvable tablets, oral solution or powder for dissolution mixed with a n appropriate volume of water or juice. Adult Dose for Prevention of Hypokalemia Parenteral: 10 to 40 mEq potassium chloride for injection diluted in an appropr iate amount and type of solution to be intravenously infused once at a rate not to exceed 40 mEq/hour. Oral: 10 to 20 mEq orally once a day given in equally div ided doses using formulations which include normal-release tablets or capsules, extended-release tablets or capsules, dissolvable tablets, oral solution or powd er for dissolution mixed with an appropriate volume of water or juice. Pediatric Dose for Hypokalemia Parenteral: 0.5 to 1 mEq/kg/dose (maximum dose 30 mEq) pot assium chloride for injection diluted in an appropriate amount and type of solut ion to be intravenously infused once at a rate not to exceed 0.3 to 0.5 mEq/kg/h our. Oral: 2 to 5 mEq/kg/day orally in equally divided doses using age-appropria te oral dosage formulations. Pediatric Dose for Prevention of Hypokalemia Oral: 1 to 2 mEq/kg/day orally in equally divided doses using age-appropriate oral dos age formulations. Therapeutic actions Principal intracellular cation of most bod y tissues, participates in a number of physiologic processes maintaining intracellul ar tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, a nd smooth muscle, maintenance of normal renal function; also plays a role in car bohydrate metabolism and various enzymatic reactions. Indications Prevention and correction of potassium deficiency; when associated with alkalosis, use potassi um chloride; when associated with acidosis, use potassium acetate, bicarbonate, citrate, or gluconate IV: Treatment of cardiac arrhythmias due to cardiac glycos ides Adverse effects Dermatologic: Rash GI: Nausea, vomiting, diarrhea, abdomina l discomfort, GI obstruction, GI bleeding, GI ulceration or perforation Hematolo gic: Hyperkalemia increased serum K+, ECG changes (peaking of T waves, loss of P wav es, depression of ST segment, prolongation of QTc interval) Local: Tissue slough ing, local necrosis, local phlebitis, and venospasm with injection Contraindicat ions Contraindicated with allergy to tartrazine, aspirin (tartrazine is found in some preparations marketed as Kaon-Cl, Klor-Con); severe renal impairment with oliguria, anuria, azotemia; untreated Addison s disease; hyperkalemia; adynamia epis odica hereditaria; acute dehydration; heat cramps; GI disorders that delay passa ge in the GI tract. Use cautiously with cardiac disorders, especially if treated with digitalis, pregnancy, lactation. Nursing considerations Assessment History : Allergy to tartrazine, aspirin; severe renal impairment; untreated Addison s disea se; hyperkalemia; adynamia episodica hereditaria; acute dehydration; heat cramps , GI disorders that cause delay in passage in the GI tract, cardiac disorders, l actation Physical: Skin color, lesions, turgor; injection sites; P, baseline ECG ; bowel sounds, abdominal examination; urinary output; serum electrolytes, serum bicarbonate Interventions Arrange for serial serum potassium levels before and during therapy. Administer liquid form to any patient with delayed GI emptying. Administer oral drug after meals or with food and a full glass of water to decre ase GI upset. Caution patient not to chew or crush tablets; have patient swallow tablet whole. Mix or dissolve oral liquids, soluble powders, and effervescent t ablets completely in 3 8 oz of cold water, juice, or other suitable beverage, and ha

ve patient drink it slowly. Arrange for further dilution or dose reduction if GI effects are severe. Agitate prepared IV solution to prevent layering of potassium; do not add potassium to an IV bottle in the hanging position. Monitor IV injection sites regularly for necrosis, tissue sloughing, phlebitis. Monitor cardiac rhyt hm carefully during IV administration. Caution patient that expended wax matrix capsules will be found in the stool. Caution patient not to use salt substitutes . Teaching points Take drug after meals or with food and a full glass of water t o decrease GI upset. Do not chew or crush tablets, swallow tablets whole. Mix or dissolve oral liquids, soluble powders, and effervescent tablets completely in 3 8 ounces of cold water, juice, or other suitable beverage, and drink it slowly. Ta ke the drug as prescribed; do not take more than prescribed. Do not use salt sub stitutes. You may find wax matrix capsules in the stool. The wax matrix is not a bsorbed in the GI tract. Have periodic blood tests and medical evaluation. You m ay experience these side effects: Nausea, vomiting, diarrhea (taking the drugs w ith meals, diluting them further may help). Report tingling of the hands or feet , unusual tiredness or weakness, feeling of heaviness in the legs, severe nausea , vomiting, abdominal pain, black or tarry stools, pain at IV injection site. Read more at Nurseslabs.com Kalium Durule (Potassium Chloride) Drug Study